



An Anthem Company

# NEW YORK Provider Communications

## Empire expands specialty pharmacy clinical site of care (level of care) drug list

Published: Aug 1, 2018 - **Products & Programs** / Pharmacy

Effective for dates of service on and after November 1, 2018, the following specialty pharmacy codes from new or current medical policies or clinical UM guidelines will be included in our existing specialty pharmacy clinical site of care review process.

Empire’s prior authorization clinical review of these specialty pharmacy drugs will be managed by AIM Specialty Health® (AIM), a separate company.

View the [Clinical Site of Care drug list](#) and [Clinical Site of Care pre-service clinical review FAQs](#) for more information.

Medical Policy or Clinical Guideline	Drug	Code
CG-DRUG-78	HemlibraTM	Q9995
CG-DRUG-89	SublocadeTM	Q9991 Q9992
CG-DRUG-89	Probuphine®	J0570
CG-DRUG-05	Retacrit®	Q5106

**URL:** <https://providernews.empireblue.com/article/empire-expands-specialty-pharmacy-clinical-site-of-care-level-of-care-drug-list-1>

**Featured In:**

August 2018 Empire Provider Newsletter

Services provided by Empire HealthChoice HMO, Inc. and/or Empire HealthChoice Assurance, Inc. licensees of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans, serving residents and businesses in the 28 eastern and southeastern counties of New York State. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. All external sites will open in a new browser window. Please view our Website Privacy Policy for more information.